Latest in Finance

Dipharma acquires LogixX Pharma to expand UK pharmaceutical presence

Dipharma has acquired UK-based LogixX Pharma, establishing a direct commercial presence in the UK and creating a platform for future launches of medicines targeting rare and metabolic diseases

Find out more
Dipharma acquires LogixX Pharma to expand UK pharmaceutical presence

Siemens named Leader in IDC MarketScape assessment of life sciences R&D technology

Siemens named Leader in IDC MarketScape assessment of life sciences R&D technology

The company has been recognised for its end-to-end digital capabilities, AI-enabled portfolio and open Smart Lab Ecosystem in IDC’s 2026 assessment of life sciences R&D...
See more
Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

VintaBio’s assignee is seeking bids for its cGMP facility, equipment and proprietary AAV technology as gene therapy contract manufacturers face overcapacity
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Merck KGaA divests US CDMO business to Lonza

Merck KGaA divests US CDMO business to Lonza

Merck KGaA will sell its US CDMO business to Lonza in a deal worth hundreds of millions of Swiss francs, expanding Lonza's US manufacturing footprint and marking a strategic shift for Merck
Codis completes demolition and begins construction on PSD-4 expansion at Haverhill

Codis completes demolition and begins construction on PSD-4 expansion at Haverhill

Expansion strengthens Codis’ UK pathway from formulation development through to commercial-scale manufacturing
Panthera expands Glasgow clinical research capacity with new centre at Health Innovation Hub

Panthera expands Glasgow clinical research capacity with new centre at Health Innovation Hub

Purpose-built facility will support Phase II and III trials and broaden participation across Glasgow and the west of Scotland
Adalvo expands biosimilars portfolio with Romiplostim programme acquisition from Enzene

Adalvo expands biosimilars portfolio with Romiplostim programme acquisition from Enzene

Acquisition accelerates Adalvo’s expansion into complex biologics and strengthens its biosimilars portfolio across development and commercialisation
Samplix secures backing to accelerate Xdrop’s commercial expansion in antibody discovery

Samplix secures backing to accelerate Xdrop’s commercial expansion in antibody discovery

WLan-led financing reaches a €25m first closing, comprising €3m in new capital and €22m in shareholder convertible-bond conversions
From scattered machine data to smarter production decisions

From scattered machine data to smarter production decisions

GEA's digital tools are being developed to help pharmaceutical production and maintenance teams bring equipment information, service support and performance data closer together

Latest posts in Finance

More tubes, more choice: Recipharm expands sterile creams and ointments

More tubes, more choice: Recipharm expands sterile creams and ointments

Recipharm expands its sterile manufacturing capacity with a new cream and ointment line at Odivelas, Portugal, which is able to produce 8–15 million units per year
LGM Pharma acquires Sannova Analytical to expand pharma testing services

LGM Pharma acquires Sannova Analytical to expand pharma testing services

The acquisition adds GLP bioanalysis, nitrosamine impurity testing and extractables and leachables services to LGM Pharma’s pharmaceutical testing capabilities
Merck to acquire Silence Therapeutics in $1.3bn RNA deal

Merck to acquire Silence Therapeutics in $1.3bn RNA deal

The acquisition will add a Phase III-ready siRNA therapy for polycythaemia vera to Merck’s rare disease pipeline, strengthening the German group’s precision medicine strategy
CellBxHealth signs new statement of work with US-based pharmaceutical company

CellBxHealth signs new statement of work with US-based pharmaceutical company

The Parsortix platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis
Malvern Panalytical acquires Dimer Instruments to expand biopharma analysis

Malvern Panalytical acquires Dimer Instruments to expand biopharma analysis

The purchase strengthens Malvern Panalytical’s biopharmaceutical characterisation capabilities, building on the development of its high-throughput Zetasizer Core stability screening platform
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Bayer invests $2.2bn in new US pharmaceutical manufacturing site

Bayer invests $2.2bn in new US pharmaceutical manufacturing site

Bayer will build a new modular pharmaceutical manufacturing campus in New Albany, Ohio, with drug substance production expected to begin in 2031
Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager

Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager

The Swiss pharma company has agreed to pay $575m upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases
SK pharmteco commits $200m to US small molecule and peptide manufacturing expansion

SK pharmteco commits $200m to US small molecule and peptide manufacturing expansion

The five-year investment adds GMP kilo-scale peptide purification, new development laboratories and upgraded manufacturing suites — creating 100 high-skilled roles as the CDMO strengthens domestic API supply chain resilience alongside its existing Ireland and South Korea expansions
You need to be a subscriber to read this article.
Click here to find out more.
BioNTech closes four sites after failed sale process as post-COVID vaccine sales slump

BioNTech closes four sites after failed sale process as post-COVID vaccine sales slump

The closure of three German facilities and the Singapore plant should free up to €500m annually, redirecting capital into BioNTech's late-stage oncology pipeline as the company pivots away from pandemic-era mRNA vaccine manufacturing
Roche signs $2bn Atavistik Bio deal for allosteric drug discovery

Roche signs $2bn Atavistik Bio deal for allosteric drug discovery

Roche and Atavistik Bio will use the biotech’s AMPS platform to discover oral small-molecule treatments for cardiovascular, renal and metabolic diseases

Sponsor Promoted Content

Gerresheimer reports stable Q3 earnings despite weaker nine-month performance

Gerresheimer reports stable Q3 earnings despite weaker nine-month performance

The packaging manufacturer recorded third-quarter revenue of €605m, up 8% year on year, while adjusted EBITDA remained broadly stable at €103m
Streamlining supply chains from clinical trial to commercial scale

Streamlining supply chains from clinical trial to commercial scale

Vetter’s Ayse Hizli discusses commercial supply chain planning, digital visibility, resilience and cold-chain management from clinical development to market launch
Lonza upgrades organic growth model and mid-term financial ambitions at capital Markets Day; Q3 2026 in line with expectations

Lonza upgrades organic growth model and mid-term financial ambitions at capital Markets Day; Q3 2026 in line with expectations

At its Capital Markets Day in Vacaville, California, Lonza reports progress of its One Lonza Strategy to deliver long-term, profitable, above-market growth
Gerresheimer improves EcoVadis rating and retains Gold status

Gerresheimer improves EcoVadis rating and retains Gold status

Company increases its score to 82 out of 100 points, ranking in the top 5% of rated companies and the top 1% for sustainable procurement
Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the...
SPI Pharma and Colorcon announce strategic global partnership

SPI Pharma and Colorcon announce strategic global partnership

Partnership combines complementary expertise to help pharmaceutical formulators address complex solid oral dose development challenges
Gerresheimer successfully completes sale of Centor

Gerresheimer successfully completes sale of Centor

Proceeds will be used to lower Gerresheimer’s debt
Gerresheimer reports stronger Q2 as adjusted EBITDA rises more than 50%

Gerresheimer reports stronger Q2 as adjusted EBITDA rises more than 50%

Drug delivery demand supports second-quarter growth as Gerresheimer prepares for a stronger second half
Grand opening ceremony for IMA Life North America in Tonawanda, USA

Grand opening ceremony for IMA Life North America in Tonawanda, USA

The new facility covers an area of 120,000 square feet and supports the company’s production of state-of-the-art pharmaceutical equipment, producing life-saving patient...
Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Long-term agreement extends manufacturing commitments through 2033 and takes cumulative contract value beyond USD 21.9 billion
Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Preliminary results: Revenues of 524 million EUR, adjusted EBITDA of 66 million EUR; stronger second half of the year expected
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation